BioVersys Reports Corporate Highlights and Key Financials for the Full Year 2024

BASEL, Switzerland, March 26, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR BV100: Positive Phase 2 VABP trial read-out with excellent safety and efficacy dataAlpibectir: Phase 2a EBA trial delivered very strong proof of conceptPreclinical candidates from BioVersys’ two proprietary platforms continue to progressFull Year 2024 operating income of CHF 1.2 million and net loss of CHF 18.7 millionSuccessful financing activities in 2024, including Series C financing round of app